New combo therapy shows promise for rare lung cancer

NCT ID NCT05380713

Completed Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding low-dose chemotherapy to radiation before surgery, followed by immunotherapy after surgery, could help people with malignant mesothelioma. Thirty participants were enrolled. The goal was to see if this approach boosts the immune system's ability to fight the cancer and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclophosphamide, tremelimumab, durvalumab
What this could lead to: If successful, this combination approach could improve immune response and survival for people with malignant mesothelioma.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply widely. The treatment involves multiple drugs with potential side effects, and it's not yet proven to be better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant mesothelioma mesothelioma Mesothelioma, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MESOTHELIOMA, MALIGNANT

Contacts and locations

Locations

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.